Surgical site infections (SSIs) account for 20% of all HAIs and are associated with increased morbidity, length of hospital stay, readmission rates, and healthcare costs.Costs due to SSIs have been recently reported to be $3.45–$10.07 billion in the United States. Because of this significant economic burden as well as high expectations of their prevention, reducing SSIs has become a major target of quality improvement initiatives, especially in the era of expanding healthcare costs. Thus, estimating the cost of SSIs has been a matter of great interest and the number of healthcare economic studies has increased.
Accurate estimation of the HAI costs has important implications for hospitals, patients, and payers. Decisions concerning the extent of resources that hospitals assign to infection control (IC) and the incentives third-party payers provide to reduce infection rates require accurate information.
Five retrospective studies were conducted using IBM MarketScan (Ann Arbor, MI, USA) Commercial Claims and Encounters (CCAE), Medicare Supplemental and Coordination of Benefits (MDCR), andMulti-State Medicaid (MDCD) databases. The studies suggests that our traditional healthcare surveillance strategies (i.e., CDC-NHSN or ACSNSQIP) that collected data within a 30-day time period and 90-day for implants would likely miss a number of these post-operative infections that occur (detected) beyond this period of time. Therefore, underestimating the personal and fiscal impact to both the patient and the healthcare system in general.
|File Size:||568 kb|
|File Size:||1210 kb|
|File Size:||634 kb|
|File Size:||701 kb|
|File Size:||482 kb|